Multivalent circular mRNA vaccines for melanoma immunotherapy
Official title: Multivalent Small Circular mRNA Vaccines for Melanoma Combination Immunotherapy
Funded at University of Michigan at Ann Arbor · NIH-11370686 · Data updated 2026-11-12
A cancer vaccine approach using tiny circular mRNA vaccines aimed at boosting immune responses against melanoma in combination with existing immunotherapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | July 17, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,689,879 |
| NIH project number | 4R01CA286122-03 |
| Project ID | NIH-11370686 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with melanoma or at-risk individuals eligible for immunotherapy combinations may be considered for future clinical testing as the program progresses.
✕Less likely to help
Patients not eligible for vaccine-based approaches or those with contraindications to immunotherapies may not benefit from this approach.
What this research studies
This project develops a novel, highly stable circular mRNA vaccine platform designed to deliver multiple melanoma-related antigens. It aims to generate strong, durable CD8+ T cell responses by targeting antigen-presenting cells and lymph nodes, with the goal of enhancing the effectiveness of immune checkpoint blockade. The work includes formulation in nanoparticles and evaluation of bioavailability, biodistribution, and potential for long-lasting immunity in preclinical models. If successful, it could lead to improved treatment options for patients with melanoma who do not fully respond to current therapies.
Why it matters
Potential benefit: If successful, patients with melanoma could experience stronger and more durable responses to immunotherapy, potentially improving survival and quality of life.
How similar studies have gone: Other cancer vaccine approaches have shown potential in preclinical and early clinical studies, but circular mRNA vaccines for melanoma in combination with ICB are still investigational.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Zhu, Guizhi — University of Michigan at Ann Arbor
- Study coordinator: Zhu, Guizhi
Related research
Other NIH-funded projects on the same topics.
-
Overcoming Melanoma Treatment Resistance with a Special IL-18 Approach
A Yale-led project tests a special engineered IL-18 immune signal to help melanoma patients who don’t fully respond to current therapies.
-
Prebiotic diet to boost gut health and improve immunotherapy response in melanoma
A diet-based approach using prebiotic foods and nutrition counseling is studied alongside standard immunotherapy to help melanoma patients respond better and reduce side effects.
-
New approach to overcome resistance to immunotherapy in melanoma
A new strategy targets a key pathway in melanoma to boost the effectiveness of immune-based therapies for patients whose cancer resists treatment.
-
Lymph Node–Targeted Co-delivery for Melanoma Immunotherapy
Aimed at improving melanoma treatment, this project tests a targeted vaccine approach that helps the body’s immune system better attack skin cancer.
-
Multifunctional nanoparticles to boost melanoma immunotherapy
A new nanoparticle approach using ultrasound-triggered systems aims to make melanoma immunotherapy work better for patients who don’t respond well to current treatments.
-
Enhancing melanoma immune therapy through DNA methylation-boosted T cells
A doctor-led program at Yale will help patients with melanoma by using specially trained CD4 helper T cells that are epigenetically enhanced to fight cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.